The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice.
Ribavirin [1-(beta-d-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide] is the treatment of choice for hepatitis C virus infection. Ribavirin is a substrate of several nucleoside transporters, including the equilibrative nucleoside transporter (Ent) and the concentrative nucleoside transporter 2. To determine the role of Ent1 in ribavirin absorption and erythrocyte distribution, we examined its pharmacokinetics in Ent1-null mice. After intravenous administration, we found that the erythrocyte area under the curve (AUC(0-12 h)) was reduced 3.05-fold along with 2.63-fold reduction of erythrocyte versus plasma AUC ratio in the Ent1(-/-) mice, whereas there was no significant difference in the plasma AUC(0-12 h) between Ent1(+/+) and Ent1(-/-) mice. After 48 h, we found a similar fraction of ribavirin or total radioactivity excreted in the urine between the Ent1(+/+) and Ent1(-/-) mice. After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice. It is interesting that at the highest dose, the dose-normalized plasma AUC(0-30 min), AUC(0-12 h), and C(max) in the Ent1(+/+) mice were decreased 4.0-, 3.8-, and 3.4-fold, respectively, compared with the lowest dose, suggesting absorption was saturated at the highest dose we used. The dose-normalized plasma AUC(0-12 h) was 3.7- and 1.5-fold lower at the lowest and the highest dose, respectively, in the Ent1(-/-) mice compared with those of the Ent1(+/+) mice. Our findings indicate that Ent1 plays a significant role in the oral absorption and erythrocyte distribution of ribavirin.
Endres
Christopher J
CJ
Department of Pharmaceutics, University of Washington, Seattle, 98195, USA.
Moss
Aaron M
AM
Govindarajan
Rajgopal
R
Choi
Doo-Sup
DS
Unadkat
Jashvant D
JD
D000042:Absorption / Q000187:drug effects / Q000235:genetics; D000284:Administration, Oral; D000818:Animals; D004305:Dose-Response Relationship, Drug; D033721:Equilibrative Nucleoside Transporter 1 / Q000096:biosynthesis / Q000097:blood / Q000235:genetics* / Q000493:pharmacokinetics; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009061:Mouth Mucosa / Q000187:drug effects / Q000378:metabolism; D033703:Nucleoside Transport Proteins / Q000097:blood / Q000502:physiology*; D012254:Ribavirin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D014018:Tissue Distribution / Q000187:drug effects / Q000235:genetics
D033721:Equilibrative Nucleoside Transporter 1; D033703:Nucleoside Transport Proteins; D012254:Ribavirin